Accentia BioPharmaceuticals Company Profile

18:49 EDT 22nd June 2018 | BioPortfolio

Our mission is to identify, develop, and market innovative biopharmaceuticals to fulfill unmet medical needs which alleviate human suffering caused by disease. Accentia BioPharmaceuticals is a vertically-integrated biopharmaceuticals company focused on the acquisition, development and commercialization of late stage specialty pharmaceuticals and biologics for targeted therapeutics. Corporate Background Accentia BioPharmaceuticals, Inc (Nasdaq:ABPI) is a vertically-integrated specialty biopharmaceutical company, formed by the Hopkins Capital Group, LLC and affiliates to acquire late-stage targeted therapeutics and to use patented delivery technologies to enhance the performance of these therapeutics. The Company consists of two wholly-owned subsidiaries, and a majority, controlling interest in a third company. Together, these assets provide for a comprehensive ability to commercialize biopharmaceuticals. Accentia partners with physicians, insurers, and pharmaceutical manufacturers to guide optimal drug development and patient care, both in the United States and in Europe. Accentia BioPharmaceuticals is focused on the commercialization of "targeted" therapeutics in patent-protected drug delivery technologies related to respiratory, oncology and critical care. Targeted therapeutics represent a rapidly growing market in pharmaceuticals, as well as in private equity spending with nearly $700 million already invested to date in 2003. Indeed the genomic revolution now offers the key means to identify targeted therapeutics. Targeted therapeutics may be synthetic chemicals or naturally occurring products called biologics, such as nucleotides, peptides, cytokines, monoclonal antibodies, or cells which restrict their action to specific cellular targets, thereby reducing undesirable collateral damage (i.e. toxicity), while boosting efficacy. As such, their extraordinary safety profiles enhance the likelihood of accelerated access to the market and their performance profiles encourage enthusiastic adoption by specialists dealing with difficult disease states. Accentia BioPharmaceuticals has chosen to accelerate its organic growth through a combination of mergers and acquisitions of companies, product acquisitions, and in-licensing of late-stage development products. Accentia, as a later-stage company with full capabilities from development to specialized distribution and a rich pipeline of products, is well-positioned to become a market leader in the Biopharmaceutical industry.


324 South Hyde Park Ave., Suite 350
United States of America


Phone: (813) 864-2554
Fax: (813) 258-6912

News Articles [177 Associated News Articles listed on BioPortfolio]

5 Top Weekly NASDAQ Biotech Stocks: Eiger BioPharmaceuticals Leads with 81.62 Percent

Eiger BioPharmaceuticals, Arqule, Galectin Therapeutics, MEI Pharma and BioDelivery Sciences were last week's top gainers on the NASDAQ. The post 5 Top Weekly NASDAQ Biotech Stocks: Eiger BioPharmace...

New international partnership promises great potential for next-generation biopharmaceuticals

There are a multitude of challenges associated with the production of next-generation biopharmaceuticals and vaccines. The Austrian Centre of Industrial Biotechnology and the BOKU - University of Natu...

Synpromics to partner with Lonza to improve biopharmaceuticals manufacturing

Synpromics has partnered with Lonza Pharma & Biotech to further develop its inducible promoter system and enhance manufacturing of biopharmaceuticals.

Global and Chinese Biopharmaceuticals Industry, 2017 Market Research Report [Report Updated: 29122017] Prices from USD $3000

The 'Global and Chinese Biopharmaceuticals Industry, 20122022 Market Research Report' is a professional and indepth study on the current state of the global Biopharmaceuticals industry with a focus on...

Apotex And Intas Biopharmaceuticals Extend Their Collaborative Development Of Biosimilars To Include Pegfilgrastim

Apotex Inc. of Canada and Intas Biopharmaceuticals Limited (IBPL) of India have extended their business agreement to develop a biosimilar version of pegfilgrastim, a protein that is used to treat neut...

Gallus BioPharmaceuticals: Mark Bamforth talks about saving jobs, local support and the importance of finding the right investment partners.

In this episode of PharmaTelevision News Review, Fintan Walton talks to Mark Bamforth, President and CEO of Gallus BioPharmaceuticals.

Takeda to sell Techpool to Chinese JV partners

Takeda Pharmaceutical has agreed to divest its its majority shareholding of 51.34% in Guangdong Techpool Bio-Pharma (Techpool), a China-based firm focused on urinary protein biopharmaceuticals and pro...

Alder BioPharmaceuticals licenses non-exclusive rights to Teva's eptinezumab

As part of a patent litigation settlement, Teva Pharmaceutical Industries Ltd. licensed Alder BioPharmaceuticals Inc. non-exclusive worldwide rights (excluding Japan and Korea) to develop, manufacture...

Drugs and Medications [1 Associated Drugs and Medications listed on BioPortfolio]

Thrombin human [Ethicon, Inc]

These highlights do not include all the information needed to use EVITHROM safely and effectively. See full prescribing information for EVITHROM.EVITHROM, Thrombin, Topical (Human)For Topical Use Only...

PubMed Articles [30 Associated PubMed Articles listed on BioPortfolio]

The importance of biosimilars medicines for private and statutory health insurance.

Patented biopharmaceuticals generate huge costs for private and statutory health insurance. Exactly ten years ago, off-patent biopharmaceuticals, also referred to as 'biosimilars medicines', became av...

Surfactants as Stabilizers for Biopharmaceuticals: An Insight into the Molecular Mechanisms for Inhibition of Protein Aggregation.

Surfactants are common stabilizers, often added to biopharmaceuticals formulations, but the mechanisms at the basis of their activity are unclear. The aim of this work is to provide insight into the m...

Next Generation Biopharmaceuticals: Product Development.

Therapeutic proteins show a rapid market growth. The relatively young biotech industry already represents 20 % of the total global pharma market. The biotech industry environment has traditionally bee...

Development and validation of a bioassay to evaluate binding of adalimumab to cell membrane-anchored TNFα using flow cytometry detection.

Physicochemical and structural properties of proteins used as active pharmaceutical ingredients of biopharmaceuticals are determinant to carry out their biological activity. In this regard, the assays...

Surface-induced crystallization of pharmaceuticals and biopharmaceuticals: a review.

Despite crystallization wide occurrence in pharmaceutical industry, deep understanding and fine control of the process remain tricky issues. Nevertheless, the successful manufacturing of finished phar...

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Nicotine Vaccination and Nicotinic Receptor Occupancy

This is a molecular imaging research study designed to examine how much nicotine gets into the brain before and after vaccination with NicVAX, a nicotine vaccine developed by Nabi Biopharm...

A Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine

Haemophilus influenza type b (Hib) remains a serious global health threat associated with high mortality and morbidity in young children. In China, The overall impact of Hib-related infect...

Companies [185 Associated Companies listed on BioPortfolio]

Accentia Biopharmaceuticals, Inc.

Headquartered in Tampa, Florida, Accentia Biopharmaceuticals, Inc. (OTCQB: “ABPIQ”) is committed to making the autoimmune disease therapy, Revimmune™, available to ...

Accentia BioPharmaceuticals

Our mission is to identify, develop, and market innovative biopharmaceuticals to fulfill unmet medical needs which alleviate human suffering caused by disease. Accentia BioPharmaceuticals is a vertic...

Biovest International

Biovest International Inc, is a majority-owned subsidiary of Accentia Biopharmaceuticals Inc., a vertically-integrated specialty biopharmaceutical company with services to commercialize targeted thera...

Itero Biopharmaceuticals, Inc.

Itero Biopharmaceuticals, Inc. is a specialty biopharmaceutical company focused on the development and commercialization of protein therapeutics that offer significant clinical an...

Bechtel Group Biopharmaceuticals Production

Design, construction, and validation of facilities for production of human biopharmaceuticals utilizing either fermentation or cell culture, facilities maintenance & operation for the virtual organiza...

More Information about "Accentia BioPharmaceuticals" on BioPortfolio

We have published hundreds of Accentia BioPharmaceuticals news stories on BioPortfolio along with dozens of Accentia BioPharmaceuticals Clinical Trials and PubMed Articles about Accentia BioPharmaceuticals for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Accentia BioPharmaceuticals Companies in our database. You can also find out about relevant Accentia BioPharmaceuticals Drugs and Medications on this site too.

Quick Search


Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

Corporate Database Quicklinks

Searches Linking to this Company Record